Blog
RSS FeedPosted by Michael Wonder on 05 Apr 2023
Are German drug pricing regulations chasing some drug makers away, causing them to withdraw products from the market?
5 April 2023 - Germany’s pharmaceutical market is the most important one on the European continent. ...
Posted by Michael Wonder on 15 Feb 2023
Germany proposes to fix shortages in certain medicines
15 February 2023 - Germany's health ministry on Tuesday vowed to fix shortages in medicines for children, antibiotics and cancer ...
Posted by Michael Wonder on 06 Dec 2022
Germany's use of reference pricing for biologics: lessons for the US
5 December 2022 - A redesign of consumer cost sharing in the US is important to accelerate the adoption of biosimilars ...
Posted by Michael Wonder on 26 Oct 2022
Germany significantly tightens drug pricing and reimbursement laws
26 October 2022 - The German regulation of pricing and reimbursement of pharmaceuticals is probably one of the most complicated legal ...
Posted by Michael Wonder on 12 Apr 2022
Prospective measures to combat rising drug prices in Germany
13 April 2022 - This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to ...
Posted by Michael Wonder on 15 Mar 2022
Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
15 March 2022 - Hansa Biopharma completes the AMNOG reimbursement process for Idefirix in Germany. ...
Posted by Michael Wonder on 24 Nov 2021
Germany's Government to be eyes backdated drug price cuts
24 November 2021 - Germany's prospective three-party government plans to cut prices retroactively for recently-launched prescription drugs to keep health ...
Posted by Michael Wonder on 16 Jun 2021
German law makers seek to ease reimbursement for advanced therapies
15 June 2021 - Advanced therapy trade group The Alliance for Regenerative Medicine has highlighted the passage of a new ...
Posted by Michael Wonder on 22 Apr 2021
Bluebird’s withdrawal of therapy from Germany could chill talks over gene therapy prices across Europe
22 April 2021 - When Bluebird Bio secured European approval for its gene therapy to treat beta thalassaemia in 2019, ...
Posted by Michael Wonder on 22 Apr 2021
Novartis to discontinue sales of Piqray in Germany
21 April 2021 - The sale of Piqray (alpelisib) will be discontinued by Novartis in accordance with Section 4 (7) ...
Posted by Michael Wonder on 13 Aug 2020
Predictors of negotiated prices for new drugs in Germany
13 August 2020 - In Germany, all new, innovative medicines are subject to an early benefit assessment by the German Federal ...
Posted by Michael Wonder on 11 Jul 2020
How can cancer drug prices better match their benefits? Germany offers a cost-saving model
10 July 2020 - After Germany revamped its approach to purchasing medicines a decade ago, the prices negotiated by the ...
Posted by Michael Wonder on 07 Jul 2020
Lessons from the impact of price regulation on the pricing of anti-cancer drugs in Germany
7 July 2020 - Worldwide spending on prescription drugs has increased dramatically in recent years. Although this increase has been particularly ...
Posted by Michael Wonder on 03 Jun 2020
Lower prices and greater patient access — lessons from Germany’s drug purchasing structure
3 June 2020 - The German system for determining drug prices features collective negotiations on the part of competing health plans. ...
Posted by Michael Wonder on 23 Mar 2020
Determinants of orphan drug prices in Germany
21 March 2020 - Legislation introduced in 2011 in Germany has instituted an early benefit assessment of newly licensed pharmaceuticals with ...